Glycemia and Antibiotic Efficacy in Diabetic Recurrent UTIs

Al-Mustansiriyah University

Status

Completed

Conditions

T2DM (Type 2 Diabetes Mellitus)

Treatments

Drug: ciprofloxacin 500 mg tablet

Study type

Interventional

Funder types

Other

Identifiers

NCT07188935

MustansiriyahU ,80 ,3/m9/2024

Details and patient eligibility

About

This study looked at how blood sugar control affects treatment of repeated urinary tract infections (UTIs) in people with type 2 diabetes. Ninety-nine patients at Al-Zahraa Teaching Hospital in Iraq were included. Some patients had good blood sugar control, while others did not. All were treated with antibiotics, and doctors checked if the infection was cured after 14 days and if it came back within 30 days. The study helps show how diabetes management can affect recovery from UTIs and the chance of infection returning.

Full description

Recurrent urinary tract infections (rUTIs) are a frequent complication among patients with type 2 diabetes mellitus (T2DM), associated with impaired immune function, glycosuria, and increased risk of antimicrobial resistance. While UTIs are common in both diabetic and non-diabetic patients, recurrence rates and treatment failures are higher in T2DM. Few prospective studies have evaluated the effect of glycemic control on antimicrobial response in this population.

This prospective comparative study enrolled 99 patients with recurrent UTIs, including 58 with T2DM, at Al-Zahraa Teaching Hospital, Wasit Province, Iraq. Patients with diabetes were stratified into groups based on glycemic control (good vs. poor). Antimicrobial therapy was administered according to hospital guidelines, and treatment response was evaluated after 14 days (clinical cure). Patients were followed for 30 days to monitor recurrence.

The primary objective was to assess whether glycemic status influences antimicrobial treatment outcomes in patients with rUTIs. Secondary objectives included evaluating recurrence rates and identifying potential risk factors for treatment failure. Findings from this study highlight the importance of optimizing glycemic control as part of the overall management of recurrent UTIs in patients with T2DM.

Enrollment

99 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients age >18 years, both sex
Patient with known history of T2DM at least 1 year
Patients diagnosed with rUTI according to the positive GUE as in practice guideline
Patients with different glycemic status according to the HbA1c level, and on different treatment for T2DM accordingly.
Patients with non-diabetic rUTI as active comparator.
Patients who had the ability to communicate to answer study questionnaire.

Exclusion criteria

Type 1 diabetic patients on insulin therapy were excluded.
T2DM Patients who were using Sodium-glucose co-transporter-2 inhibitors (SGLT-2) (because of their renal -related side effect).
Patients who received any antimicrobial treatment within the last 72 hours of their enrollment.
Women patients with recurrent vaginitis or urinary incontinence.
Men patients with BPH or over flow incontinence ( as a cause for r UTI).
Patients with chronic disease other than T2DM that may cause rUTI ( eg. CKD, Spinal cord injury. kidney stone).
Pregnancy and lactation